Advertisement
Advertisement
CRDF
Cardiff Oncology, Inc. Common Stock
0.79
USDSponsored
-0.01
-0.74%
Nov 10, 15:59 UTC -5
Closed
After-Market
0.79
-0.01
-0.98%
Cardiff Oncology, Inc. Common Stock (CRDF) Earnings
CRDF Earnings Reports
Positive Surprise Ratio
CRDF beat 25 of 42 last estimates.
60%
Next Report
Date of Next Report
Feb 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
$85.00K
/-$0.15
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
-65.02%
/+36.36%
Cardiff Oncology, Inc. Common Stock earnings per share and revenue
On Nov 06, 2026, CRDF reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.15 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 80.75 thousand, with a --% difference. The market reacted with a -2.46% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.15 USD, with revenue projected to reach 85.00 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Cardiff Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Cardiff Oncology, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Cardiff Oncology, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -2.46%, changed from $0.91 before the earnings release to $0.89 the day after.
When is Cardiff Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 22, 2027.
What are the forecasts for Cardiff Oncology, Inc. Common Stock's next earnings report?
Based on --
analysts, Cardiff Oncology, Inc. Common Stock is expected to report EPS of -$0.15 and revenue of $85.00K for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.